Drug Trial Radar · NCT05935748
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Jul 28, 2023
Primary completion
Jun 30, 2025
Study completion Sep 4, 2025
Sponsor
- Lead sponsor
- NiKang Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Jul 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.
Conditions
- ccRCC
- Clear Cell Renal Cell Carcinoma
- Kidney Cancer
- Kidney Neoplasms
- Renal Cancer
- Renal Neoplasms
- Recurrent Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Refractory Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Carcinoma
- Neoplasms
- Carcinoma, Renal Cell
- Neoplasms, Glandular and Epithelial
- Neoplasm by Histology
- Adenocarcinoma
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
Interventions
NKT2152Drug
Oral HIF2a inhibitor
palbociclibDrug
a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
sasanlimabOther
an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicity (DLT) Events During the DLT Monitoring Period (First 28 Days of Dosing) in the Lead-in PhaseTime frame: 28 days
- Objective Response Rate (ORR) Determined by the InvestigatorTime frame: 1 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Northwestern University - Feinberg School of Medicine
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan-Rogel Cancer Center
Ann Arbor, Michigan
Nebraska Cancer Specialists
Omaha, Nebraska
Memorial Sloan Kettering Cancer Center
New York, New York
UT Southwestern Medical Center
Dallas, Texas
University of Virginia Health System
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.